Loss-of-function genetic screen unveils synergistic efficacy of PARG inhibition with combined 5-fluorouracil and irinotecan treatment in colorectal cancer

Abstract

Background: Colorectal cancer (CRC) remains a major global health concern, partly due to resistance to therapy and the lack of new effective treatments for advanced disease. The combination of 5-Fluorouracil (5FU, a thymidylate synthase inhibitor) and irinotecan (a topoisomerase 1 inhibitor) is widely used in first-line and subsequent treatments. This study aimed to identify novel therapeutic targets to enhance combinatorial therapy, improving treatment efficacy and durability of response.

Methods: We performed a loss-of-function screen using HT29 CRC cell line and a retroviral library containing 7296 shRNAs targeting 912 chromatin genes. Cells were then treated with 5FU and SN38 (the active metabolite of irinotecan) or left untreated for 4 weeks. Genes enriched in resistant clones were identified through next-generation sequencing. Amongst candidate genes, PARG was selected for functional validation.

Results: CRISPR/Cas9-mediated knockout (HT29 PARG-KO) resulted in increased global poly(ADP-ribosyl)ation after 5FU and SN38 treatment. PARG depletion led to reduced cell viability and increased apoptosis, particularly after 5FU exposure. Pharmacological PARG inhibition (PDD00017273) synergised with 5FU and SN38 across three CRC models (HT29, DLD1, HT115). In vivo, HT29 PARG-KO xenografts were more sensitive to 5FU. Immunohistochemical analysis of 170 CRC patient tumours revealed that positive PARG expression correlated with poor response to 5FU + Irinotecan, increased liver metastases, and worse long-term survival.

Conclusions: Our findings highlight PARG as a promising therapeutic target for CRC, where its inhibition enhances the efficacy of standard chemotherapy.

Keywords

5FU / colorectal cancer / FUIRI / irinotecan / loss-of-function screening / PARG / PDD00017273

References

[1] Saltz LB, Cox JV, Blanke C, et al. Irinotecan Study Group. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med. 2000; 343(13): 905-914.

[2] Moreta-Moraleda C, Queralt C, Vendrell-Ayats C, Forcales S, Martínez-Balibrea E. Chromatin factors: ready to roll as biomarkers in metastatic colorectal cancer? Pharmacol Res. 2023; 196:106924.

[3] Plasencia C, Rooney PH, Taron M, Martinez-Balibrea E, McLeod HL, Abad A. Chromosomal imbalance maps of human 5FU-resistant colorectal cancer cell lines: implications in the analysis of 5FU-acquired resistance mechanisms. Int J Oncol. 2003; 22(5): 945-953.

[4] Fellmann C, Hoffmann T, Sridhar V, et al. An optimized microRNA backbone for effective single-copy RNAi. Cell Rep. 2013; 5(6): 1704-1713.

[5] Fellmann C, Zuber J, McJunkin K, et al. Functional identification of optimized RNAi triggers using a massively parallel sensor assay. Mol Cell. 2011; 41(6): 733-746.

[6] Ritchie ME, Dai Z, Sheridan JM, et al. edgeR: a versatile tool for the analysis of shRNA-seq and CRISPR-Cas9 genetic screens. F1000Res. 2014; 3: 95.

[7] Hu Q, Klages-Mundt N, Wang R, et al. The ARK assay is a sensitive and versatile method for the global detection of DNA–protein crosslinks. Cell Rep. 2020; 30(4): 1235-1245.

[8] Guichard S, Cussac D, Hennebelle I, Bugat R, Canal P. Sequence-dependent activity of the irinotecan-5FU combination in human colon-cancer model HT-29 in vitro and in vivo. Int J Cancer. 1997; 73(5): 729-734.

[9] Britten CD, Hilsenbeck SG, Eckhardt SG, et al. Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model. Cancer Res. 1999; 59(5): 1049-1053.

[10] Reipsch F, Biersack B, Lucas H, Schobert R, Mueller T. Imidazole analogs of vascular-disrupting combretastatin A-4 with pleiotropic efficacy against resistant colorectal cancer models. Int J Mol Sci. 2021; 22(23):13082.

[11] Aston WJ, Hope DE, Nowak AK, Robinson BW, Lake RA, Lesterhuis WJ. A systematic investigation of the maximum tolerated dose of cytotoxic chemotherapy with and without supportive care in mice. BMC Cancer. 2017; 17(1): 684.

[12] Aranda E, Valladares M, Martinez-Villacampa M, et al. Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors Study. Ann Oncol. 2009; 20(2): 251-257.

[13] Martinez-Balibrea E, Plasencia C, Ginés A, et al. A proteomic approach links decreased pyruvate kinase M2 expression to oxaliplatin resistance in patients with colorectal cancer and in human cell lines. Mol Cancer Ther. 2009; 8(4): 771-778.

[14] Martinez-Cardús A, Martinez-Balibrea E, Bandrés E, et al. Pharmacogenomic approach for the identification of novel determinants of acquired resistance to oxaliplatin in colorectal cancer. Mol Cancer Ther. 2009; 8(1): 194-202.

[15] Ruiz De Porras V, Bystrup S, Martínez-Cardús A, et al. Curcumin mediates oxaliplatin-acquired resistance reversion in colorectal cancer cell lines through modulation of CXC-Chemokine/NF-κB signalling pathway. Sci Rep. 2016; 6:24675.

[16] Sveen A, Bruun J, Eide PW, et al. Colorectal cancer consensus molecular subtypes translated to preclinical models uncover potentially targetable cancer cell dependencies. Clin Cancer Res. 2018; 24(4): 794-806.

[17] Berg KCG, Eide PW, Eilertsen IA, et al. Multi-omics of 34 colorectal cancer cell lines—a resource for biomedical studies. Mol Cancer. 2017; 16(1): 1-16.

[18] Jossé R, Martin SE, Guha R, et al. ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase I inhibitors by disabling DNA replication initiation and fork elongation responses. Cancer Res. 2014; 74(23): 6968.

[19] Villaruz LC, Kelly K, Waqar SN, et al. NCI 9938: phase I clinical trial of ATR inhibitor berzosertib (M6620, VX-970) in combination with irinotecan in patients with advanced solid tumors. J Clin Oncol. 2022; 40 (suppl 16): 3012-3012.

[20] Clinical Trial: NCT04535401—My Cancer Genome. Accessed February 14, 2025. https://www.mycancergenome.org/content/clinical_trials/NCT04535401/

[21] Study Details | A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors | ClinicalTrials.gov. Accessed October 7, 2024. https://clinicaltrials.gov/study/NCT05787587

[22] Study Details | A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies | ClinicalTrials.gov. Accessed October 7, 2024. https://clinicaltrials.gov/study/NCT06395519

[23] Holleran JP, Rodems TS, Sharma S, et al. Abstract 2083: discovery of ETX-19477, a novel and selective PARG inhibitor with high potency against tumors with underlying replication stress. Cancer Res. 2024; 84(suppl 6): 2083-2083.

[24] Abed M, Muñoz D, Seshadri V, et al. Abstract 6093: iDE161, a potential first-in-class clinical candidate PARG inhibitor, selectively targets homologous-recombination-deficient and PARP inhibitor resistant breast and ovarian tumors. Cancer Res. 2023; 83(suppl 7): 6093-6093.

[25] Harrision D, Gravells P, Thompson R, Bryant HE. Poly(ADP-Ribose) Glycohydrolase (PARG) vs. Poly(ADP-Ribose) Polymerase (PARP)—function in genome maintenance and relevance of inhibitors for anti-cancer therapy. Front Mol Biosci. 2020; 7: 191.

[26] Gravells P, Neale J, Grant E, et al. Radiosensitization with an inhibitor of poly(ADP-ribose) glycohydrolase: a comparison with the PARP1/2/3 inhibitor olaparib. DNA Repair. 2018; 61: 25-36.

[27] Tsuda K, Kurasaka C, Ogino Y, Sato A. Genomic and biological aspects of resistance to selective poly(ADP-ribose) glycohydrolase inhibitor PDD00017273 in human colorectal cancer cells. Cancer Rep. 2023; 6(2):e1709.

[28] James DI, Smith KM, Jordan AM, et al. First-in-class chemical probes against Poly(ADP-ribose) Glycohydrolase (PARG) inhibit DNA repair with differential pharmacology to Olaparib. ACS Chem Biol. 2016; 11(11): 3179-3190.

[29] Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm. 2016; 7(2): 27.

[30] Li Q, Li M, Wang YL, et al. RNA interference of PARG could inhibit the metastatic potency of colon carcinoma cells via PI3-kinase/Akt pathway. Cell Physiol Biochem. 2012; 29(3-4): 361-372.

[31] Győrffy B. Integrated analysis of public datasets for the discovery and validation of survival-associated genes in solid tumors. Innovation. 2024; 5(3):100625.

[32] Diesch J, Le Pannérer MM, Winkler R, et al. Inhibition of CBP synergizes with the RNA-dependent mechanisms of Azacitidine by limiting protein synthesis. Nat Commun. 2021; 12(1): 6060.

[33] Jin MH, Oh DY. ATM in DNA repair in cancer. Pharmacol Ther. 2019; 203:107391.

[34] Rosen EM. BRCA1 in the DNA damage response and at telomeres. Front Genet. 2013; 4(Jun):52895.

[35] Katheeja MN, Das SP, Das R, Laha S. BRCA1 interactors, RAD50 and BRIP1, as prognostic markers for triple-negative breast cancer severity. Front Genet. 2023; 14:1035052.

[36] Feng X, Koh DW. Roles of poly(ADP-ribose) glycohydrolase in DNA damage and apoptosis. Int Rev Cell Mol Biol. 2013; 304: 227-281.

[37] Nicolae CM, Aho ER, Choe KN, et al. A novel role for the mono-ADP-ribosyltransferase PARP14/ARTD8 in promoting homologous recombination and protecting against replication stress. Nucleic Acids Res. 2015; 43(6): 3143-3153.

[38] Sethy C, Kundu CN. 5-Fluorouracil (5-FU) resistance and the new strategy to enhance the sensitivity against cancer: implication of DNA repair inhibition. Biomed Pharmacother. 2021; 137:111285.

[39] Wyatt MD, Wilson DM. Participation of DNA repair in the response to 5-fluorouracil. Cell Mol Life Sci. 2009; 66(5): 788-799.

[40] Pommier Y. Drugging topoisomerases: lessons and challenges. ACS Chem Biol. 2013; 8(1): 82-95.

[41] Rack JGM, Palazzo L, Ahel I. (ADP-ribosyl)hydrolases: structure, function, and biology. Genes Dev. 2020; 34(5-6): 263-284.

[42] Liu C, Vyas A, Kassab MA, Singh AK, Yu X. The role of poly ADP-ribosylation in the first wave of DNA damage response. Nucleic Acids Res. 2017; 45(14): 8129-8141.

[43] Tentori L, Leonetti C, Scarsella M, et al. Poly(ADP-ribose) glycohydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide. Eur J Cancer. 2005; 41(18): 2948-2957.

[44] Matanes E, López-Ozuna VM, Octeau D, et al. Inhibition of Poly ADP-Ribose glycohydrolase sensitizes ovarian cancer cells to Poly ADP-Ribose polymerase inhibitors and platinum agents. Front Oncol. 2021; 11:745981.

[45] Li J, Koczor CA, Saville KM, et al. Overcoming temozolomide resistance in glioblastoma via enhanced NAD+ bioavailability and inhibition of poly-ADP-Ribose glycohydrolase. Cancers. 2022; 14(15): 3572.

[46] Fabbrizi MR, Nickson CM, Hughes JR, et al. Targeting OGG1 and PARG radiosensitises head and neck cancer cells to high-LET protons through complex DNA damage persistence. Cell Death Dis. 2024; 15(2): 150.

[47] Zhou X, Hao Q, Lu H. Mutant p53 in cancer therapy—the barrier or the path. J Mol Cell Biol. 2019; 11(4): 293-305.

[48] Sun Y, Chen J, Huang S yin N, et al. PARylation prevents the proteasomal degradation of topoisomerase I DNA-protein crosslinks and induces their deubiquitylation. Nature Commun.. 2021; 12(1): 1-16.

[49] Finan JM, Di Niro R, Park SY, et al. The polymeric fluoropyrimidine CF10 overcomes limitations of 5-FU in pancreatic ductal adenocarcinoma cells through increased replication stress. Cancer Biol Ther. 2024; 25(1):2421584.

[50] Haber AO, Jain A, Mani C, et al. AraC-FdUMP[10](CF10) is a next generation fluoropyrimidine with potent antitumor activity in PDAC and synergy with PARG inhibition. Mol Cancer Res. 2021; 19(4): 565.

[51] Wang JQ, Tang Y, Li QS, et al. PARG regulates the proliferation and differentiation of DCs and T cells via PARP/NFκB in tumour metastases of colon carcinoma. Oncol Rep. 2019; 41(5): 2657-2666.

[52] Marques M, Jangal M, Wang LC, et al. Oncogenic activity of poly (ADP-ribose) glycohydrolase. Oncogene. 2019; 38(12): 2177-2191.

[53] Yu M, Chen Z, Zhou Q, et al. PARG inhibition limits HCC progression and potentiates the efficacy of immune checkpoint therapy. J Hepatol. 2022; 77(1): 140-151.

[54] Study Details | A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies | ClinicalTrials.gov. Accessed February 14, 2025. https://clinicaltrials.gov/study/NCT06395519

[55] Study Details | A Study of PARG Inhibitor IDE161 in Participants with Advanced Solid Tumors | ClinicalTrials.gov. Accessed February 14, 2025. https://clinicaltrials.gov/study/NCT05787587

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.